Table 3.
Univariate and multivariate analyses of overall survival using the new prognostic factors.
| Variables | Univariable | Multivariable 1 | Multivariable 2 | ||||
|---|---|---|---|---|---|---|---|
| N (event) | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Age ≥55 years | 101 (81) | 0.92 (0.64-1.32) | 0.635 | ||||
| Female gender | 34 (33) | 1.38 (0.92-2.06) | 0.117 | ||||
| Metachronous type | 61 (48) | 0.48 (0.33-0.69) | <.001 | ||||
| Nephrectomy | 89 (70) | 0.34 (0.23-0.50) | <.001 | 0.37 (0.24-0.55) | <.001 | 0.38 (0.25-0.56) | <.001 |
| Body mass index | 145 (118) | 0.96 (0.90-1.02) | 0.159 | ||||
| KPS≤80 | 12 (10) | 1.02 (0.53-1.96) | 0.955 | ||||
| DFI≤1year | 106 (88) | 2.04 (1.40-2.99) | <.001 | ||||
| mMSKCC, favorable | 48 (33) | 1 | (0.003) | ||||
| intermediate | 74 (64) | 1.77 (1.16-2.70) | 0.009 | ||||
| poor | 12 (12) | 2.83 (1.45-5.54) | 0.002 | ||||
| Heng, favorable | 14 (7) | 1 | <.001 | ||||
| intermediate | 94 (79) | 3.11 (1.42-6.78) | 0.004 | ||||
| poor | 24 (21) | 6.46 (2.70-15.46) | <.001 | ||||
| Lung metastasis | 113 (91) | 0.76 (0.52-1.11) | 0.152 | ||||
| Liver metastasis | 33 (32) | 1.92 (1.28-2.89) | 0.002 | 1.88 (1.21-2.94) | 0.005 | ||
| Bone metastasis | 54 (48) | 1.12 (0.78-1.61) | 0.533 | ||||
| Brain metastasis | 18 (13) | 0.98 (0.55-1.75) | 0.955 | ||||
| Hb, M<13, F<11.5 | 90 (81) | 2.04 (1.41-2.94) | <.001 | 1.83 (1.23-2.71) | 0.003 | 1.71 (1.16-2.51) | 0.007 |
| Platelet ≥400 | 19 (16) | 2.51 (1.45-4.34) | 0.001 | ||||
| Neutrophil ≥7500 | 28 (24) | 2.17 (1.37-3.42) | 0.001 | 2.58 (1.55-4.30) | <.001 | ||
| Lymphocyte≥1500 | 60 (53) | 1.71 (1.19-2.45) | 0.003 | ||||
| NLR | 152 (125) | 1.06 (1.03-1.09) | <.001 | 1.07 (1.04-1.11) | <.001 | ||
| LDH ≥300 | 13 (11) | 1.37 (0.72-2.58) | 0.338 | ||||
| Corrected Calcium ≥10 | 11 (11) | 1.73 (0.92-3.24) | 0.087 | ||||
| Albumin <3.5 | 23 (21) | 3.77 (2.28-6.22) | <.001 | ||||
| Alkaline phosphatase≥104 | 50 (43) | 1.83 (1.23-2.70) | 0.003 | 1.63 (1.08-2.45) | 0.019 | 1.73 (1.16-2.58) | 0.008 |
| AST≥40 | 12 (12) | 3.60 (1.95-6.65) | <.001 | ||||
| ALT≥40 | 101 (81) | 0.92 (0.64-1.32) | 0.635 | ||||
| De Retis ratio | 34 (33) | 1.38 (0.92-2.06) | 0.117 | 1.34 (1.09-1.64) | 0.006 | ||
KPS, Karnofsky performance score; DFI, disease-free interval; Hb, hemoglobin; NLR, neutrophil-to-lymphocyte ratio; LDH, lactate dehydrogenase; AST, aspartate transaminase; ALT, alanine transaminase; HR, hazard ratio; CI, confidence interval.
Multivariable 1 (uni p-value ≤0.15 without LDH) used with gender, metachronous type, nephrectomy, DFI<1, liver mets, Hb, platelet, neutrophil, Lymphocyte, corrected ca, Alkaline phosphatase, AST.
Multivariable 2 (uni p-value ≤0.15 without LDH) used with gender, metachronous type, nephrectomy, DFI<1, liver mets, Hb, platelet, corrected ca, Alkaline phosphatase, NLR, de retis ratio.